Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Inventory: 2021-2024

  • Ascendis Pharma A's Inventory rose 40.52% to $315.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $315.9 million, marking a year-over-year increase of 40.52%. This contributed to the annual value of $319.9 million for FY2024, which is 42.33% up from last year.
  • As of Q4 2024, Ascendis Pharma A's Inventory stood at $315.9 million, which was up 40.52% from $224.8 million recorded in Q4 2023.
  • Ascendis Pharma A's Inventory's 5-year high stood at $315.9 million during Q4 2024, with a 5-year trough of $86.3 million in Q4 2021.
  • For the 3-year period, Ascendis Pharma A's Inventory averaged around $224.7 million, with its median value being $224.8 million (2023).
  • Data for Ascendis Pharma A's Inventory shows a peak YoY spiked of 68.62% (in 2023) over the last 5 years.
  • Over the past 4 years, Ascendis Pharma A's Inventory (Quarterly) stood at $86.3 million in 2021, then soared by 54.55% to $133.3 million in 2022, then soared by 68.62% to $224.8 million in 2023, then soared by 40.52% to $315.9 million in 2024.
  • Its last three reported values are $315.9 million in Q4 2024, $224.8 million for Q4 2023, and $133.3 million during Q4 2022.